Open AccessImplications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study
Author(s) -
Yael Kusne,
Heidi E. Kosiorek,
Matthew Buras,
Patricia M. Verona,
Kyle Coppola,
Kelley Rone,
Curtiss B. Cook,
Nina J. Karlin
Publication year - 2021
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2020-0190
Subject(s) - diabetes mellitus , medicine , intensive care medicine , bioinformatics , endocrinology , biology
Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control. Patients & methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005–2017), and survival compared (Kaplan–Meier and Cox proportional hazards). Mixed models compared hemoglobin A 1c (HbA 1c ) and glucose during the year after cancer diagnosis. Results: Three-year overall survival was 72% (95% CI: 60–86%) for DM patients versus 80% (95% CI: 70–92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56–3.16; p = 0.51); mean DM HbA 1c , 7.3%. Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.